Remove Cell Based Assays Remove Disease Remove International
article thumbnail

An industry leader’s perspective on the complexity of scientific data

Drug Target Review

Janette Thomas leads a small biotech company (Five Alarm Bio) 1 on a mission to develop drugs targeting the chronic diseases associated with ageing. Her company’s focus includes dementia, muscle wasting, and chronic wounds – diseases that disproportionately affect the elderly. Reference 1 Five Alarm Bio. cited 2024 Oct 17].

article thumbnail

Exploring alternatives to animal testing in drug discovery

Drug Target Review

allowing researchers to use “certain alternatives to animal testing, including cell-based assays and computer models, to obtain an exemption from the FDA to investigate the safety and effectiveness of a drug.” Three-dimensional organoids have been a popular choice in testing drugs to treat cancer and disease.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions

The Pharma Data

ASLAN believes ASLAN003 has the potential to bethe most potent oral inhibitor of DHODH currently in development for autoimmune disease, more than 30 times more potent at inhibiting the DHODH enzyme than teriflunomide. In preclinical studies, ASLAN003 was shown to be efficacious in animal models of MS and other autoimmune diseases.

article thumbnail

Article FDA Thank You Draft guidance on potency assays for CGT products garners extensive stakeholder input

Agency IQ

Cell-based assays , while more complex to develop and use, offer another option for characterizing product activity at a slightly higher level, allowing sponsors to measure the further downstream effects of products (e.g., morphological cell changes or alterations in protein production or expression).

article thumbnail

Machine learning’s growing importance in researching cells

Drug Target Review

This is especially true in domains such as protein structure, predictive binding kinetics, and even in larger systemic investigations like cell migration models or disease progression. Ultimately, multi-omics represents an opportunity to generate high-fidelity, richly informative datasets that are often internally orthogonal.

Research 116